# Efficacy and Safety of Enteric-coated Mycophenolate Sodium in Combination With Two Corticosteroid Regimens for the Treatment of Lupus Nephritis Flare

> **NCT00423098** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 81 (actual)

## Conditions studied

- Lupus Nephritis

## Interventions

- **DRUG:** Mycophenolate sodium
- **DRUG:** Prednisone
- **DRUG:** Methylprednisolone

## Key facts

- **NCT ID:** NCT00423098
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02
- **Primary completion:** 2009-11
- **Final completion:** 2009-11
- **Target enrollment:** 81 (ACTUAL)
- **Last updated:** 2011-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00423098

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00423098, "Efficacy and Safety of Enteric-coated Mycophenolate Sodium in Combination With Two Corticosteroid Regimens for the Treatment of Lupus Nephritis Flare". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00423098. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*